---
title: "Foundation-Model Whole-Slide AI plus PRAME IHC for Melanoma Diagnosis"
id: "medrxiv-19-integrating-histopathology-foundation-models-and-prame-immunohistochemistry-in"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-19-integrating-histopathology-foundation-models-and-prame-immunohistochemistry-in"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.14.26368089v1?rss=1"
published_at: "2026-11-16T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Foundation-Model Whole-Slide AI plus PRAME IHC for Melanoma Diagnosis
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-19-integrating-histopathology-foundation-models-and-prame-immunohistochemistry-in
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.14.26368089v1?rss=1)
- **Published At:** 2026-11-16T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators evaluated a diagnostic framework that combines a foundation-model–based whole-slide image analysis pipeline (Virchow2 with the STAMP framework), automated prediction of morphological features, and manual **PRAME** immunohistochemistry. - The retrospective cohort comprised 1,000 melanocytic lesions; models were trained on 800 cases and tested on a temporally held-out set of 200 cases. - A slide-level malignancy classifier achieved high discrimination on the test set (test **AUROC** 0.970; AUPRC 0.984), indicating strong overall performance of the foundation model. - Individual AI models predicted established histopathological criteria with high accuracy: ulceration (AUROC 0.991) and dermal mitoses (AUROC 0.966) are examples of well-discriminated features. - Predicting **PRAME** expression from H&E alone produced lower accuracy (AUROC 0.776–0.780 for PRAME scores 4 and 0), so direct inference of IHC from morphology was limited. - An integrated model that combined the slide-level malignancy score, AI-predicted morphological features, and manual **PRAME** status produced an AUROC of 0.972 (AUPRC 0.975), effectively comparable to the standalone classifier. - In multivariable analysis, a **PRAME** score of 4 versus 0 had a strong association with malignancy (adjusted OR 35.04; 95% CI 17.39–74.62), as the study team reported. - The authors deposited aggregated prediction data, analysis scripts, and model configurations on GitHub and archived them on Zenodo; raw whole-slide images and identifiable clinical metadata were not shared due to institutional privacy rules. - The study received ethics approval from the Ethics Committee of Technische Universitaet Dresden (reference BO-EK-172042024).
## Clinical Analysis & Structured Key Points
Integrating Histopathology Foundation Models and PRAME Immunohistochemistry in Melanoma Diagnosis | medRxiv Skip to main content Integrating Histopathology Foundation Models and PRAME Immunohistochemistry in Melanoma Diagnosis View ORCID Profile Frank Friedrich Gellrich , Alaska Kistner , View ORCID Profile Claudia Guenther , View ORCID Profile Cosima Hufnagel , View ORCID Profile Sarah Hobelsberger , Joerg Laske , View ORCID Profile Stefan Beissert , View ORCID Profile Daniela Aust , View ORCID Profile Gustavo Baretton , Nick Reidow , View ORCID Profile Mildred Sergon , View ORCID Profile Jakob Nikolas Kather , View ORCID Profile Narmin Ghaffari Laleh doi: https://doi.org/10.64898/2026.11.14.26368089 Frank Friedrich Gellrich 1 Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Frank Friedrich Gellrich For correspondence: frankfriedrich.gellrich{at}ukdd.de Alaska Kistner 1 Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Claudia Guenther 2 Department of Dermatology, Faculty of Medicine and University Hospital Tuebingen, Eberhard Karls University of Tuebingen, Tuebingen, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Claudia Guenther Cosima Hufnagel 1 Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Cosima Hufnagel Sarah Hobelsberger 1 Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sarah Hobelsberger Joerg Laske 1 Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Stefan Beissert 1 Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Stefan Beissert Daniela Aust 3 Institute of Pathology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Daniela Aust Gustavo Baretton 3 Institute of Pathology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Gustavo Baretton Nick Reidow 3 Institute of Pathology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Mildred Sergon 3 Institute of Pathology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Mildred Sergon Jakob Nikolas Kather 4 Else Kroener Fresenius Center for Digital Health, Technical University Dresden, Dresden, Germany Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jakob Nikolas Kather Narmin Ghaffari Laleh 4 Else Kroener Fresenius Center for Digital Health, Technical University Dresden, Dresden, Germany Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Narmin Ghaffari Laleh Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background: The histopathological diagnosis of challenging melanocytic lesions remains limited by substantial interobserver variability. Although computational pathology foundation models demonstrated promising diagnostic performance, their predictions are often difficult to interpret in terms of established criteria. Objective: We evaluated a diagnostic framework combining foundation-model-based whole-slide image analysis, automated prediction of morphological features, and manually assessed PRAME immunohistochemistry. Methods: Using the Virchow2 foundation model and STAMP framework, we analyzed a retrospective cohort of 1,000 melanocytic lesions undergoing PRAME immunohistochemistry. Models were trained on 800 cases and evaluated on a temporally held-out test cohort of 200 cases. Results: The slide-level malignancy classifier achieved a test AUROC of 0.970 (AUPRC 0.984). Separate models predicted established histopathological criteria with high discrimination, including ulceration (AUROC 0.991) and dermal mitoses (AUROC 0.966). In contrast, predicting PRAME expression from H&E images alone showed lower performance (AUROC 0.776-0.780 for PRAME scores 4 and 0). An integrated model combining the slide-level malignancy score, AI-predicted morphological features, and manual PRAME status achieved an AUROC of 0.972 (AUPRC 0.975), comparable to the standalone classifier. In multivariable analysis, PRAME score 4 versus 0 was strongly associated with malignancy (adjusted OR 35.04, 95% CI 17.39-74.62). Conclusions: These findings demonstrate the feasibility of combining foundation-model-based histopathological analysis with established morphological criteria and PRAME immunohistochemistry. Although the integrated framework did not substantially improve overall discrimination, it provides a structured approach for incorporating complementary histopathological and immunohistochemical information into AI-assisted assessment of melanocytic lesions. Competing Interest Statement JNK holds shares in StratifAI, Synagen, Spira Labs, Tremont AI, and Saterra AI; is Co-PI on institutional research grants from GSK and AstraZeneca, and declares honoraria or consulting fees from AstraZeneca, Bayer, Bioptimus, Daiichi Sankyo, Eisai, Janssen, Merck, MSD, Novartis, BMS, Roche, and Pfizer. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Ethics Committee of Technische Universitaet Dresden gave ethical approval for this work (reference number: BO-EK-172042024; decision dated July 17, 2024). The study was conducted in accordance with the Declaration of Helsinki and involved the retrospective analysis of pseudonymized, routinely collected clinical and histopathological data, without the inclusion of identifiable patient information or images. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The aggregated and anonymized prediction data, R analysis scripts, and model configurations required to reproduce the findings of this study are openly available in the GitHub repository at https://github.com/ffgellrich/ai-prame-dermatopathology and permanently archived on Zenodo (https://doi.org/10.5281/zenodo.24220711). Due to institutional data privacy regulations regarding sensitive patient health records, raw whole-slide images (WSIs) and unanonymized clinical metadata cannot be made publicly available. https://github.com/ffgellrich/ai-prame-dermatopathology Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted November 16, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Integrating Histopathology Foundation Models and PRAME Immunohistochemistry in Melanoma Diagnosis Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Integrating Histopathology Foundation Models and PRAME Immunohistochemistry in Melanoma Diagnosis Frank Friedrich Gellrich , Alaska Kistner , Claudia Guenther , Cosima Hufnagel , Sarah Hobelsberger , Joerg Laske , Stefan Beissert , Daniela Aust , Gustavo Baretton , Nick Reidow , Mildred Sergon , Jakob Nikolas Kather , Narmin Ghaffari Laleh medRxiv 2026.11.14.26368089; doi: https://doi.org/10.64898/2026.11.14.26368089 Share This Article: Copy Citation Tools Integrating Histopathology Foundation Models and PRAME Immunohistochemistry in Melanoma Diagnosis Frank Friedrich Gellrich , Alaska Kistner , Claudia Guenther , Cosima Hufnagel , Sarah Hobelsberger , Joerg Laske , Stefan Beissert , Daniela Aust , Gustavo Baretton , Nick Reidow , Mildred Sergon , Jakob Nikolas Kather , Narmin Ghaffari Laleh medRxiv 2026.11.14.26368089; doi: https://doi.org/10.64898/2026.11.14.26368089 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (642) Allergy and Immunology (923) Anesthesia (355) Cardiovascular Medicine (5038) Dentistry and Oral Medicine (496) Dermatology (430) Emergency Medicine (680) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1701) Epidemiology (16322) Forensic Medicine (36) Gastroenterology (1243) Genetic and Genomic Medicine (7310) Geriatric Medicine (758) Health Economics (1098) Health Informatics (5325) Health Policy (1477) Health Systems and Quality Improvement (1842) Hematology (599) HIV/AIDS (1386) Infectious Diseases (except HIV/AIDS) (16517) Intensive Care and Critical Care Medicine (1205) Medical Education (701) Medical Ethics (157) Nephrology (755) Neurology (7638) Nursing (380) Nutrition (1137) Obstetrics and Gynecology (1300) Occupational and Environmental Health (1044) Oncology (3755) Ophthalmology (1101) Orthopedics (413) Otolaryngology (470) Pain Medicine (506) Palliative Medicine (144) Pathology (722) Pediatrics (1871) Pharmacology and Therapeutics (758) Primary Care Research (789) Psychiatry and Clinical Psychology (6168) Public and Global Health (10032) Radiology and Imaging (2550) Rehabilitation Medicine and Physical Therapy (1532) Respiratory Medicine (1277) Rheumatology (663) Sexual and Reproductive Health (810) Sports Medicine (601) Surgery (807) Toxicology (109) Transplantation (320) Urology (309)
## Related Clinical Research

- [UV-related Tumor Mutational Burden Predicts Melanoma Mortality in Stage II/III InterMEL Cohort](https://medichelpline.com/clinical-feed/medrxiv-11-uv-induced-mutations-are-associated-with-melanoma-specific-mortality-in-stage.md)
- [ESMO recap: Reactions to Merck and Moderna’s mRNA cancer vaccine data](https://medichelpline.com/clinical-feed/stat-news-1-assessing-merck-and-moderna-s-mrna-cancer-vaccine.md)
- [Deep learning on routine histopathology adds prognostic value beyond AJCC stage in early-stage mel](https://medichelpline.com/clinical-feed/medrxiv-15-deep-learning-reveals-prognostic-information-beyond-ajcc-stage-in-routine.md)
- [Single‑cell atlas of 189 colorectal tumors links tumor biology to worse outcomes in young patients](https://medichelpline.com/clinical-feed/stat-news-0-stat-new-atlas-of-colorectal-tumors-sheds-light-on-why-cancers-in-young-people.md)
- [Cellular Metabolism, Immunity, and Oncogenesis: Drug Discovery Opportunities](https://medichelpline.com/clinical-feed/frontiers-in-immunology-5-editorial-cellular-metabolism-the-immune-system-and-oncogenesis-opportunities.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.